A medical device manufacturer Hancock Jaffe Laboratories (NASDAQ: HJLI) instantly jumps over 110% on 70 million shares right after informing that two additional VenoValve patients from HJLI’s first-in-man, chronic venous insufficiency (“CVI”) has significantly improved in both patients when compared to pre-surgery levels.
HJLI’s movement fully depends on the success of its newly developed devices that restore cardiac and vascular health. Sometimes good earnings results and partnerships may lift the stock a bit.
The current price is still cheap for NASDAQ fans while OTC market has almost free stocks that are near bankruptcy filing. Buying HJLI could be a nice addition to the portfolio of highly experienced short term investors.
Finance and Tech Contributor